Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis ; volume:73 ; number:10 ; day:6 ; month:8 ; year:2024 ; pages:1-13 ; date:10.2024
Cancer immunology immunotherapy ; 73, Heft 10 (6.8.2024), 1-13, 10.2024

Creator: Guo, Guangzhong
Zhang, Ziyue
Zhang, Jiubing
Wang, Dayang
Xu, Sensen
Liu, Guanzheng
Gao, Yushuai
Mei, Jie
Yan, Zhaoyue
Zhao, Ruijiao
Wang, Meiyun
Li, Tianxiao
Bu, Xingyao

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00262-024-03774-7

URN: urn:nbn:de:101:1-2411292101292.310326908832

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:34 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Guo, Guangzhong
Zhang, Ziyue
Zhang, Jiubing
Wang, Dayang
Xu, Sensen
Liu, Guanzheng
Gao, Yushuai
Mei, Jie
Yan, Zhaoyue
Zhao, Ruijiao
Wang, Meiyun
Li, Tianxiao
Bu, Xingyao
SpringerLink (Online service)

Other Objects (12)

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab

Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma

Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition

Hochschulschrift

Tumor-infiltrierende Lymphozyten beim Glioblastoma multiforme

Glioblastoma vaccine tumor therapy research progress

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors

Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

Tumor cell response to bevacizumab single agent therapy in vitro

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab

Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma

Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition

Hochschulschrift

Tumor-infiltrierende Lymphozyten beim Glioblastoma multiforme

Glioblastoma vaccine tumor therapy research progress

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors

Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

Tumor cell response to bevacizumab single agent therapy in vitro

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab

Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma

Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition

Hochschulschrift

Tumor-infiltrierende Lymphozyten beim Glioblastoma multiforme

Glioblastoma vaccine tumor therapy research progress

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors

Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

Tumor cell response to bevacizumab single agent therapy in vitro

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab

Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma

Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition

Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition

Tumor-infiltrierende Lymphozyten beim Glioblastoma multiforme

Glioblastoma vaccine tumor therapy research progress

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors

Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

Tumor cell response to bevacizumab single agent therapy in vitro

Tumor cell response to bevacizumab single agent therapy in vitro

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab

Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma

Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition

Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition

Tumor-infiltrierende Lymphozyten beim Glioblastoma multiforme

Glioblastoma vaccine tumor therapy research progress

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors

Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

Tumor cell response to bevacizumab single agent therapy in vitro

Tumor cell response to bevacizumab single agent therapy in vitro

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab

Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma

Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition

Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition

Tumor-infiltrierende Lymphozyten beim Glioblastoma multiforme

Glioblastoma vaccine tumor therapy research progress

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors

Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

Tumor cell response to bevacizumab single agent therapy in vitro

Tumor cell response to bevacizumab single agent therapy in vitro

Related objects

Reset password